Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
暂无分享,去创建一个
K. Simon | M. Pawłowska | E. Janczewska | R. Flisiak | W. Halota | J. Jaroszewicz | W. Mazur | K. Tomasiewicz | A. Piekarska | B. Lorenc | J. Klapaczyński | M. Tudrujek-Zdunek | M. Sitko | D. Zarębska-Michaluk | I. Buczyńska | D. Dybowska | A. Czauż-Andrzejuk | H. Berak | R. Krygier | J. Citko | Ł. Socha | Z. Deroń | Ł. Laurans | O. Tronina | P. Pabjan | T. Belica-Wdowik | W. Dobracki
[1] E. Heil,et al. Effectiveness of 8 Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HCV–HIV-Coinfected Patients , 2019, Antiviral therapy.
[2] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[3] L. Hurley,et al. No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] C. Hézode. Treatment of hepatitis C: Results in real life , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[5] K. Simon,et al. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. , 2017, Advances in medical sciences.
[6] B. Bacon,et al. Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients , 2017, Alimentary pharmacology & therapeutics.
[7] K. Simon,et al. Recommendations for the treatment of hepatitis C in 2017 , 2017, Clinical and experimental hepatology.
[8] K. Kowdley,et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection , 2017, Hepatology.
[9] I. Altraif. Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[10] Gamal Esmat,et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[11] K. Simon,et al. Prevalence of HCV genotypes in Poland – the EpiTer study , 2016, Clinical and experimental hepatology.
[12] P. Belperio,et al. Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients , 2016, Hepatology.
[13] K. Simon,et al. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016 , 2016, Clinical and experimental hepatology.
[14] M. Parczewski,et al. Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland , 2016, Archives of medical science : AMS.
[15] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[16] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[17] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[18] K. Qureshi,et al. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data , 2018, Journal of managed care & specialty pharmacy.
[19] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.